◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › C › CRON

Cronos Group Inc (CRON) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-09-17

Cronos Group Inc (CRON) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Stayner, Canada with about 610 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, CRON reported $149M in revenue and ($10M) in net income.

Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names.

Interactive charts & full statements → Open the CRON valuation workbench →

CRON Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Revenue	$243M	$149M	$118M	$87M	$87M	$65M	$47M	$18M	$12M	$4M	$0M	$3M	($1M)	$0M	—
Gross Profit	$81M	$62M	$25M	$12M	$15M	($18M)	($26M)	($13M)	$6M	$2M	$1M	$3M	($1M)	$0M	—
Gross Margin %	33.5%	41.4%	21.4%	13.7%	17.8%	-27.3%	-55.3%	-74.1%	51.3%	48.3%	359.7%	73.6%	105.6%	100.0%	—
Operating Income (EBIT)	$12M	($18M)	($77M)	($85M)	($111M)	($292M)	($219M)	($118M)	($20M)	($8M)	($2M)	$1M	($3M)	($1M)	$0M
Operating Margin %	5.1%	-12.0%	-65.1%	-97.2%	-128.4%	-452.2%	-469.6%	-664.2%	-168.7%	-187.9%	-516.8%	16.4%	457.7%	316.7%	—
Net Income	$70M	($10M)	$41M	($74M)	($169M)	($396M)	($73M)	$1.2B	($22M)	$3M	($1M)	$0M	($4M)	($1M)	$0M
Net Margin %	28.7%	-6.4%	34.9%	-84.8%	-194.5%	-613.5%	-156.5%	6691.6%	-178.5%	61.0%	-290.8%	8.2%	624.2%	316.7%	—
EBITDA	$24M	($3M)	($50M)	($72M)	($91M)	($150M)	($66M)	$880M	($19M)	($5M)	($1M)	$1M	($3M)	($1M)	$0M
Earnings Per Share (EPS)	$0.18	$-0.02	$0.11	$-0.19	$-0.45	$-1.07	$-0.21	$3.48	$-0.13	$0.01	$-0.02	$0.01	$-0.13	$-0.05	$-0.04
Shares Outstanding (M)	385M	385M	386M	381M	377M	370M	352M	343M	172M	177M	78M	44M	32M	—	1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRON Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$71M	$45M	$91M	$36M	$33M	$32M	$30M	$34M
Gross Profit	$28M	$18M	$16M	$18M	$15M	$14M	$11M	$4M
Gross Margin %	40.3%	41.4%	17.7%	50.4%	43.4%	42.6%	35.7%	10.5%
Operating Income (EBIT)	$7M	($1M)	$7M	($1M)	($5M)	($4M)	($11M)	($34M)
Operating Margin %	10.5%	-3.2%	7.6%	-1.4%	-15.9%	-12.6%	-37.5%	-98.2%
Net Income	$32M	$14M	($2M)	$26M	($40M)	$6M	$44M	$8M
Net Margin %	45.5%	30.4%	-2.0%	71.4%	-118.7%	19.0%	144.3%	24.4%
EBITDA	$36M	$2M	($45M)	$31M	$0M	($1M)	($11M)	($16M)
Earnings Per Share (EPS)	$0.08	$0.04	$-0.00	$0.07	$-0.10	$0.02	$0.11	$0.02
Shares Outstanding (M)	385M	385M	385M	385M	385M	387M	387M	386M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRON Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Cash from Operations (CFO)	$55M	$26M	$19M	($43M)	($89M)	($154M)	($145M)	($98M)	($10M)	($4M)	($5M)	($1M)	($1M)	$0M
Capital Expenditures (CapEx)	$10M	$26M	$13M	$3M	$5M	$12M	$35M	$29M	$84M	$34M	$1M	$1M	$1M	$0M
Free Cash Flow (FCF)	$45M	$0M	$6M	($46M)	($94M)	($166M)	($180M)	($127M)	($94M)	($38M)	($6M)	($2M)	($2M)	$0M
FCF Margin %	18.3%	0.1%	4.8%	-53.0%	-108.3%	-256.9%	-385.8%	-711.4%	-776.8%	-926.4%	-1443.3%	-61.1%	359.7%	61.0%
Dividends Paid	—	—	—	$0M	$0M	—	$3M	$65M	$0M	$0M	$0M	$0M	$0M	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRON Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$19M	$11M	$12M	$13M	$3M	($2M)	$8M	$12M
Capital Expenditures (CapEx)	$2M	$2M	$2M	$5M	$4M	$15M	$4M	$7M
Free Cash Flow (FCF)	$17M	$9M	$10M	$9M	($1M)	($17M)	$4M	$5M
FCF Margin %	24.1%	20.0%	10.8%	24.0%	-3.0%	-54.1%	13.2%	14.7%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CRON Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Assets	$1.2B	$1.2B	$1.2B	$1.1B	$1.2B	$1.4B	$1.9B	$1.6B	$232M	$80M	$32M	$11M	$9M	$1M
Cash & Cash Equivalents	$467M	$792M	$859M	$669M	$765M	$887M	$1.1B	$901M	$24M	$7M	$3M	$1M	$1M	$0M
Total Liabilities	$62M	$54M	$55M	$44M	$72M	$63M	$218M	$256M	$35M	$12M	$7M	$2M	$1M	$0M
Total Debt (Short + Long-Term)	$0M	$0M	$1M	$1M	$1M	$3M	$1M	$0M	$0M	$4M	$3M	$1M	$0M	$0M
Total Shareholders' Equity	$1.1B	$1.1B	$1.1B	$1.1B	$1.1B	$1.3B	$1.7B	$1.3B	$148M	$88M	$25M	$8M	$8M	$1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CRON viewer.

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

ETON · Eton Pharmaceuticals Inc — $2 billion
XERS · Xeris Pharmaceuticals Inc — $1 billion
PAHC · Phibro Animal Health Corporation — $1 billion
HROW · Harrow Health Inc — $1 billion
PCRX · Pacira BioSciences, Inc. — $984 million
GLAS · Glass House Brands Inc. — $800 million
TAK · Takeda Pharmaceutical Co Ltd ADR — $60 billion
UTHR · United Therapeutics Corporation — $21 billion

← CROMPTON All “C” companies CROS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.